Trial Profile

A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UV 1 (Primary) ; Sargramostim
Indications Non-small cell lung cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms UV1-hTERT2012L
Sponsors Ultimovacs AS

Most Recent Events

16 Dec 2024 Status changed from active, no longer recruiting to completed.
25 May 2022 According to an Ultimovacs AS media release, data from this study presented at the Journal for ImmunoTherapy of Cancer and was also presented as a poster at the Cancer Immunotherapy (CIMT) annual meeting.
10 May 2022 According to an Ultimovacs AS media release, data from this trial will be presented as a poster at the upcoming Cancer Immunotherapy (CIMT) annual meeting 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com